Woman scientist working at lab bench

Intellectual Property
At Our Core Resides A Powerful,
High-Throughput Discovery Engine

Intellectual Property

Ractigen possesses a prominent IP position in RNAa and oligonucleotide delivery. At Ractigen’s core resides a powerful, high-throughput discovery engine allowing for the rapid identification of saRNAs. Our portfolio is built on composition of matter and methods of use for a growing library of therapeutic oligonucleotides. Medicinal chemistries and delivery platforms developed exclusively in-house further strength our IP estate and empower drug development.

High-Throughput
Process

Our Discovery Engine

It features a highly-refined bioinformatics algorithm integrating epigenetic datasets, design rules, and genome-wide on-target prediction tethered to in-house oligonucleotide manufacturing for saRNA synthesis followed by automated experimental validation of saRNA activity.

Labeled arrows: Genetic Sequence, Target Identification, saRNA Synthesis, and HTS
Target Gene Locus icon

Target Gene Locus

Rapidly identify all saRNAs for any single target gene

Search Algorithm icon

Search Algorithm

Highly-refined
bioinformatics algorithm

In-House Synthesis icon

In-House Synthesis

Oligonucleotide manufacturing for in-house saRNA synthesis

In vitro Screening & Gene Expression icon

In vitro Screening & Gene Expression

Automated rounds of dose-dependent gene expression

3-4 Weeks Start to Finish (All In-House)

Start to finish underline

Screen Hundreds of saRNA Candidates

Automated rounds of dose-dependent gene expression analytics and integrated de-risking safety assays allow for the screening of hundreds of saRNA candidates within 30-45 days.

Honing the Process

We are continually honing the process in pursuit of full-automation and continue to add to our ever-growing list of therapeutic genes expanding our IP estate and feeding our drug development pipeline.

Want to Discover More?

Check out our News. Below are some highlights to get you started.

GO TO NEWS >

January 27, 2022 in News Highlight

Ractigen Therapeutics closes an additional $30 million in Series A+ funding to push development of its RNAa platform

Ractigen Therapeutics today announced the closing of a Series A+ financing round totaling $30 million led by SDIC Venture Capital with participation from Eisai Co., Ltd., LC Ventures, CSSD Capital,…
Read More
February 10, 2021 in Company News

Ractigen Therapeutics closes on $17 Million Series A to advance lead program into clinical phase, led by Hillhouse Venture Capital

Ractigen Therapeutics, a leading company in the saRNA drug space, announced that it has closed a 17$ million USD (¥110 million) Series A financing round led by Hillhouse Venture Capital…
Read More
May 19, 2020 in Company News

CB Insights lists Ractigen as one of the Top RNA biotech companies in China

Today, CB Insights China published, for the first time, a top list of RNA biotech companies in China and Ractigen Therapeutics, as the only company developing RNAa therapeutics, is listed…
Read More
July 11, 2018 in Company News

Delegation from Nantong University Medical School visits Ractigen

Today, a 5-member delegation, led by the dean Professor Fei Sun, from Nantong University Medical School paid a visit to Ractigen and Rudong Life and Health Industry Park. After touring…
Read More